May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...
Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have merit” getty Stock image of baby powder Johnson & Johnson has offered ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ...
Five plaintiffs sued Johnson & Johnson on Wednesday, accusing the company of fraud through its use of a shell company's ...
TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. TAR-210 is an intravesical targeted releasing system designed ...
Shelby is an editor with an affinity for covering home improvement and repair, design and real estate trends. She also specializes in content strategy and entrepreneur coaching for small ...
May 13 (UPI) --U.S.-based Red Lobster abruptly closed more than 50 of its seafood restaurants across the country on Monday, as the company is reported to be considering Chapter 11 bankruptcy ...
Chicago Mayor Brandon Johnson sat down Monday for a wide-ranging interview with City Hall reporters Alice Yin and Jake Sheridan. Here is the full transcript of the interview, lightly edited for ...
Dallas Mayor Eric Johnson wants a City Council committee to meet as soon as possible to consider opposing severance pay for former city manager T.C. Broadnax. Johnson in a memo Thursday to Mayor ...
Benzinga - by Vandana Singh, Benzinga Editor. On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with ...